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Currently, the United States has the safest vaccine
supply in its history.
The United States’ long-standing vaccine safety
system ensures that vaccines are as safe as
possible. It detects problems rapidly and allows
us to respond. As new information and science
become available, this system is, and will continue
to be, updated and improved.
The U.S. Food and Drug Administration (FDA)
ensures the safety, effectiveness, and availability
of vaccines for the United States. Before the
FDA licenses (approves) a vaccine, the vaccine
is tested extensively by its manufacturer. FDA
scientists and medical professionals carefully
evaluate all the available information about the
vaccine to determine its safety and effectiveness.
Most common side effects of a vaccine are
identified in studies before the vaccine is licensed.
Some adverse events are so rare, however, that
they may not be detected in these studies.
Therefore, the U.S. vaccine safety monitoring
system continuously monitors for adverse events
(possible side effects) after a vaccine is licensed.
When millions of people receive a vaccine, less
common side effects that were not identified
earlier may show up.
| |Prelicensure: Vaccine Safety Testing 
The U.S. Food and Drug Administration (FDA) must license 
(approve) a vaccine before it can be used in the United States. 
FDA regulations for the development of vaccines help to ensure 
their safety, purity, potency, and effectiveness. Before a vaccine is 
approved by FDA for use by the public, results of studies on safety 
and effectiveness of the vaccine are evaluated by highly trained FDA 
scientists and doctors. FDA also inspects the vaccine manufacturing 
sites to make sure they comply with current Good Manufacturing 
Practice regulations. 
Vaccine Development
Vaccine development begins in the laboratory before any tests in 
animals or humans are done. If laboratory tests show that a vaccine 
has potential, it is usually tested in animals. If a vaccine is safe in 
animals, and studies suggest that it will be safe in people, clinical 
trials with volunteers are next. 
Clinical Trials
Typically, there are three phases of clinical trials. Vaccines that are 
being developed for children are first tested in adults. FDA sets 
guidelines for the three phases of clinical trials to ensure the safety of 
the volunteers. 
Phase 1 clinical trials focus on safety and include 20–100 healthy 
volunteers. In Phase 1, scientists begin to learn how the size of the 
dose may be related to side effects. If possible at this early stage, 
scientists also try to learn how effective the vaccine may be. 
If no serious side effects are found in Phase 1, next is Phase 2, which 
involves several hundred volunteers. This phase includes studies that 
may provide additional information on common short-term side 
effects and how the size of the dose relates to immune response. 
In Phase 3 studies, hundreds or thousands of volunteers participate. 
Vaccinated people are compared with people who have received a 
placebo or another vaccine so researchers can learn more about the 
test vaccine’s safety and effectiveness and identify common side 
effects. 
Clinical trials are conducted according to plans that FDA reviews to 
ensure the highest scientific and ethical standards. The results of the 
clinical trials are a part of FDA’s evaluation to assess the safety and 
effectiveness of each vaccine. In addition to evaluating the results of 
the clinical trials, FDA scientists and medical professionals carefully 
evaluate a wide range of information including results of studies on 
the vaccine’s physical, chemical, and biological properties, as well as 
how it is manufactured, to ensure that it can be made consistently 
safe, pure, and potent.
Adverse Events and Side Effects Adverse events reported to the 
Vaccine Adverse Event Reporting System (VAERS) are not necessarily side 
effects caused by vaccination. An adverse event is a health problem that 
happens after vaccination that may or may not be caused by a vaccine. 
By definition, a side effect has been shown to be linked to a vaccine by 
scientific studies.
   For more information on vaccines, 
vaccine-preventable diseases, and  
vaccine safety:
https://www.cdc.gov/vaccines/conversations
| Prelicensure: Vaccine Safety Testing | continued 
The trials and all other data must show that the vaccine’s benefits 
outweigh the potential risks (side effects) for people who will be 
recommended to receive the vaccine. Only if a vaccine’s benefits are 
found to outweigh its potential risks does the FDA grant a license for 
the vaccine, allowing it to be used by the public. 
| Postlicensure: Vaccine Safety Monitoring |
After vaccines are licensed, they are monitored closely as people begin 
using them. The purpose of monitoring is to watch for adverse events 
(possible side effects). Monitoring a vaccine after it is licensed helps 
ensure that the benefits continue to outweigh the risks for people who 
receive the vaccine. 
Monitoring is essential for two reasons. First, even large clinical trials 
may not be big enough to reveal side effects that do not happen very 
often. For example, some side effects may only happen in 1 in 100,000 
or 1 in 500,000 people. 
Second, vaccine trials may not include groups who might have 
different types of side effects or who might have a higher risk of 
side effects than the volunteers who got the vaccine during clinical 
trials. Examples of these groups include people with chronic medical 
conditions and pregnant women. 
If a link is found between a possible side effect and a vaccine, public 
health officials take appropriate action by first weighing the benefits of 
the vaccine against its risks to determine if recommendations for using 
the vaccine should change. 
The Advisory Committee on Immunization Practices (ACIP), a  
group of  medical and public health experts, carefully reviews safety 
and effectiveness data on vaccines as a part of its work to make 
recommendations for the use of vaccines. The ACIP modifies 
recommendations, if needed, based on safety monitoring.  
VAERS
Postlicensure monitoring begins with the Vaccine Adverse Event 
Reporting System (VAERS), a national system used by scientists at 
FDA and the Centers for Disease Control and Prevention (CDC) to 
collect reports of adverse events (possible side effects) that happen after 
vaccination. Health care professionals, vaccine manufacturers, vaccine 
recipients, and parents or family members of people who have received 
a vaccine are encouraged to submit reports to VAERS if they experience 
any adverse events after getting any vaccine. 
Scientists monitor VAERS reports to identify adverse events that 
need to be studied further. All serious reports are reviewed by 
medical professionals on a daily basis. VAERS data provide medical 
professionals at CDC and FDA with a signal of a potential adverse 
event. Experience has shown that VAERS is an excellent tool for 
detecting potential adverse events. Reports of adverse events that are 
unexpected, appear to happen more often than expected, or have 
unusual patterns are followed up with specific studies. 
VAERS data alone usually cannot be used to answer the question, 
“Does a certain vaccine cause a certain side effect?” This is mainly 
because adverse events reported to VAERS may or may not be caused 
by vaccines. There are reports in VAERS of common conditions that 
may occur by chance alone that are found shortly after vaccination. 
Investigation may find no medical link between vaccination and 
these conditions. 
VSD
Scientists use CDC’s Vaccine Safety Datalink (VSD) to do studies that 
help determine if possible side effects identified using VAERS are 
actually related to vaccination. VSD is a network of 8 managed care 
organizations across the United States. The combined population of 
these organizations is more than 24 million people. 
PRISM
To further monitor for possible vaccine side effects, FDA utilizes Post-
Licensure Rapid Immunization Safety Monitoring (PRISM). PRISM 
is the largest vaccine safety surveillance system in the United States.  
Scientists use PRISM to actively monitor and analyze data from a 
representative subset of the general population.  PRISM links data from 
health plans with data from state and city immunization registries. 
Because PRISM has access to information for over 190 million people, 
FDA is able to identify and analyze rare health outcomes that would 
otherwise be difficult to assess.
CISA
The Clinical Immunization Safety Assessment (CISA) Project is a 
collaboration between CDC and 7 medical research centers. Vaccine 
safety experts conduct individual case reviews and clinical research 
studies about vaccine safety.
Vaccine Manufacturing
Once a vaccine is licensed, FDA regularly inspects vaccine 
manufacturing facilities to make sure they are following strict 
regulations. Vaccines are manufactured in batches called lots, and 
vaccine manufacturers must test all lots of a vaccine to make sure they 
are safe, pure, and potent. Vaccine lots cannot be distributed until 
released by FDA.
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For more information on vaccines call 800-CDC-INFO (800-232-4636) 
or visit https://www.cdc.gov/vaccines.
